Search research articles

Search research articles

Related Experiment Videos

Anti-adhesion therapies.

David L Simmons¹

¹Inflammation Discovery Research, Wyeth Research, 200 CambridgePark Drive, Cambridge, MA02140, USA. dsimmons@wyeth.com

Current Opinion in Pharmacology

|June 16, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeting kinases: a new approach to treating inflammatory rheumatic diseases.

Current opinion in pharmacology·2013

Same author

Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways.

Arthritis and rheumatism·2009

Same author

What makes a good anti-inflammatory drug target?

Drug discovery today·2006

Same author

Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis.

The Journal of experimental medicine·2005

Same author

Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue.

Arthritis and rheumatism·2003

Same journal

Targeting the ischemic cascade: Review on approved and investigational stroke therapies.

Current opinion in pharmacology·2026

Same journal

Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives.

Current opinion in pharmacology·2026

Same journal

Chrono-immunotherapy in precision oncology: Circadian control of the tumor microenvironment and time-of-day optimization of immune checkpoint blockade.

Current opinion in pharmacology·2026

Same journal

Methotrexate: Integrating molecular pharmacology, systems toxicology, and precision rescue strategies.

Current opinion in pharmacology·2026

Same journal

Acupuncture and non-invasive neuromodulation-induced neuro-endocrine-immune changes associated with the amelioration of depression-like behaviors: A systematic review of animal studies.

Current opinion in pharmacology·2026

Same journal

Alopecia areata: Mechanisms, targeted therapies, and translational challenges.

Current opinion in pharmacology·2026

See all related articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Cell adhesion molecules, like LFA-1, are crucial in inflammation and targeted by new therapies. Recent drug approvals show promise but also highlight safety challenges in therapeutic development.

Area of Science:

Immunology and Pharmacology
Structural Biology

Background:

Cell adhesion molecules (CAMs) mediate inflammatory processes, making them key targets for novel therapeutics.
Advances in basic research provide structural insights into CAM function, particularly integrin-ligand interactions.

Purpose of the Study:

To review recent progress in understanding cell adhesion molecule function and therapeutic development.
To highlight structural insights and clinical advancements in targeting CAMs for inflammatory diseases.

Main Methods:

Analysis of published co-crystal structures of integrin-ligand complexes.
Review of clinical development of anti-adhesion therapeutics targeting specific CAMs.

Main Results:

Detailed structural understanding of integrin-ligand interactions, including LFA-1 with ICAM-1.

Related Experiment Videos

Successful clinical approval of efalizumab (targeting LFA-1) and natalizumab (targeting VLA-4).

Natalizumab withdrawal due to safety concerns, impacting the therapeutic landscape.

Conclusions:

Structural biology advances inform the development of integrin-targeting drugs.
Clinical success of anti-adhesion therapies is demonstrated, but safety monitoring is critical.
The field shows significant promise for novel therapeutics targeting inflammatory processes via cell adhesion molecules.